PhaseBio Pharmaceuticals Inc. (PHAS) to Offer Common Stock

Go back to PhaseBio Pharmaceuticals Inc. (PHAS) to Offer Common Stock

PhaseBio Announces Proposed Public Offering of Common Stock

March 17, 2021 5:02 PM UTC

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, PhaseBio expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of the shares to be sold in the offering are to be sold by PhaseBio. The offering is subject to market and other conditions, and there can... More